A solution of 6"-azido-(penta-NHBoc)-tobramycin ( Fig.1 (1) ) [1] (0.15 mmol, 150 mg) in CH2Cl2 (5 mL) was cooled on ice to 0°C. Trifluoroacetic acid (5mL) was added. After stirring for 2h at 0°C, the solution was concentrated in vacuo and the residue was dissolved in dimethylformamide (2.5 mL). The following compounds were added to the solution: CuI (29 mg, 0.15 mmol, 1 eq), diisopropylethylamine (50 µL, 0.30 mmol, 2 eq) and Bodipy alkyne [2] (50 mg, 0.15 mmol, 1 eq). The reaction mixture was stirred for 4 h at room temperature and then the solvent was evaporated. Purification with preparative thin layer chromatography (CH2Cl2/MeOH/NH4OH) afforded the BODIPY Tobramycin (102 mg, 0.10 mmol 68 %) as a deep orange Electrospray ionization high resolution mass spectrometry (ESI-HRMS) for C37H59BF2N10O8 [M+H] found, 821.4665; calcd, 821.4651. ESI-HRMS spectra were measured with a Waters LCT Premier XE Mass spectrometer calibrated using leucine enkephalin as an external standard. Samples were infused in water/acetonitrile/formic acid mixture (1:1:0.001 v/v/v) at 100 µl/min. The structure of BODIPY-tobramycin was confirmed using Nuclear magnetic resonance (NMR) spectroscopy (BRUKER 700MHz Avance II NMR spectrometer at 298K) ( Table 1) .

